IP Library Granted Patent US 11,013,754
Granted Patent B2
US 11,013,754 · App. 16/378,825 · Granted May 25, 2021

Compositions and methods for treating cancer

Inventors: Arul Chinnaiyan (Northville, MI); Rohit Malik (Pennington, NJ); Yajia Zhang (Ann Arbor, MI); Marcin Cieslik (Ann Arbor, MI); Sethuramasundaram Pitchiaya (Ypsilanti, MI)
Assignee: The Regents of the University of Michigan
A61K31/7105C12N15/113G01N33/57434C12N2310/11C12N2310/141
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,013,754
App. No.
16/378,825
Granted
May 25, 2021
Kind
B2
Abstract

Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of ARlnc1 for treating cancer.

Claims (12)

1. A method of treating cancer, comprising:

administering an agent that blocks the expression or activity of ARlnc1 to a subject diagnosed with cancer under conditions such that a sign or symptom of said cancer is reduced, wherein said agent comprises a nucleic acid.

2. The method of claim 1 , wherein said nucleic acid is selected from the group consisting of a siRNA, a shRNA, a miRNA, and an antisense oligonucleotide.

3. The method of claim 1 , wherein said cancer is prostate cancer.

4. The method of claim 1 , wherein said cancer expresses ARlnc1.

5. The method of claim 4 , wherein ARlnc1 is overexpressed in said cancer relative to the level of expression in non-cancerous cells.

6. The method of claim 1 , wherein said method further comprises the step of assaying a sample of said cancer for the level of expression of ARlnc1.

7. A method, comprising:

a) assaying a sample from a subject diagnosed with cancer, wherein said sample comprises cancer tissue or cells for the level of expression of ARlnc1; and

b) administering an agent that blocks the expression or activity of ARlnc1 when expression of ARlnc1 is present in said sample, wherein said agent comprises a nucleic acid.

8. The method of claim 7 , wherein said nucleic acid is selected from the group consisting of a siRNA, a shRNA, a miRNA, and an antisense oligonucleotide.

9. The method of claim 7 , wherein said cancer is prostate cancer.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 16, 2023
From: UNIVERSITY OF MICHIGAN
To: UNITED STATES GOVERNMENT
Reel/Frame 062999/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2019
From: CHINNAIYAN, ARUL; MALIK, ROHIT; ZHANG, YAJIA; CIESLIK, MARCIN; PITCHIAYA, SETHURAMASUNDARAM
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 049381/0732 →
Continuity (2)
Provisional Application 62655308 · Apr 10, 2018
Related Publication 20190307787A1 · Oct 10, 2019